Investment March 2002
Why we invested
New regulation, and a growing emphasis on workplace health management, were driving increased adoption of drug and alcohol testing across a number of industries. Medscreen was the leading UK provider with a long-standing client base in the maritime, oil and gas, transport and other sectors – and was one of the few companies able to service international demand due to its unique international collection network and secure chain of custody. This was an opportunity to back a leading company in executing a compelling growth strategy, both organically and by acquisition.
During our ownership, Medscreen delivered strong growth in sales and profits. This was aided by the acquisition of Drug Testing International, Medscreen’s largest US competitor, creating the foremost international player in its market. A considerable investment was also made in increasing Medscreen’s laboratory capacity, and in expanding into the occupational health market.
In 2006, Medscreen was sold to a strategic buyer for an undisclosed sum.
Fiona Begley,Managing Director